Acute myeloid leukemia (AML) clinical trial pipeline is robust with 100+ key pharma companies actively working in the domain. AML primarily affects older adults, and the global rise in aging populations is increasing the at-risk patient base, leading to higher diagnosis rates and demand for more effective treatments. The market is witnessing growth in targeted therapies, immunotherapies, and personalized treatment approaches.

DelveInsight’s ‘Acute Myeloid Leukemia Pipeline Insight 2025’ report provides global coverage of pipeline therapies for AML, analyzing key trends, emerging therapies, and competitive landscape dynamics. The report includes insights into clinical trial benchmarking, partnering activities, and regulatory pathways, enabling stakeholders to optimize development strategies.

The acute myeloid leukemia pipeline report showcases 100+ active players developing 150+ pipeline drugs. Key companies like HUTCHMED, Senti Biosciences, and AstraZeneca are evaluating promising therapies like HMPL-306 and IO 202 in different phases of clinical trials. Notable mechanisms of action include Isocitrate dehydrogenase inhibitors and Fms-like tyrosine kinase 3 inhibitors.

Recent developments in AML treatment space include new clinical data from Cullinan Therapeutics, the safety profile of RPT1G from Remedy Plan Therapeutics, and Orphan Drug Designation for ligufalimab from Akeso Inc. These advancements highlight the progress in developing novel therapies for AML, showcasing a promising future for patients.

For further information on acute myeloid leukemia medications, the success rate of treatments, and the latest clinical trials, stakeholders can access the comprehensive pipeline report provided by DelveInsight. The report covers a wide range of therapeutic assessments, key companies, pipeline therapies, and market insights to help make informed decisions in the AML domain.

Read more at GlobeNewswire: Acute Myeloid Leukemia Clinical Trial Pipeline Appears